AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Oral vitamin K markedly improves survival in patients with hepatocellular carcinoma, Dr. Yukihiro Koike said at the annual Digestive Disease Week.
This simple therapy works by preventing tumor extension into the portal vein, a common event that heralds greatly diminished survival in this traditionally poor-prognosis cancer, explained Dr. Koike, who is with Kanto Chuo Hospital, Tokyo.
He reported on 121 patients with hepatocellular carcinoma who were randomized to get oral vitamin K 1145 mg/day or not. All patients received conventional therapy with percutaneous tumor ablation and/or transcatheter arterial embolization.
The rate of…